Fluoroscopy in Interventional Oncology: Expanding the Therapeutic Frontier

Fluoroscopy, a dynamic X‑ray imaging modality that provides real‑time visualization of anatomical structures and interventional devices, has long been a cornerstone of minimally invasive procedures. In interventional oncology, its role has evolved from a supportive tool for basic biopsies and drainages to an essential component of complex, image‑guided cancer therapies. As treatment paradigms shift toward targeted, patient‑specific approaches, fluoroscopy is being adapted and combined with other technologies to enable higher precision, better safety profiles, and improved clinical outcomes. This article explores the emerging and expanding use cases of fluoroscopy in interventional oncology, highlighting technical advances, procedural innovations, and future directions.

The Established Foundation: Fluoroscopy’s Traditional Roles

Before delving into emerging applications, it is important to understand the established contributions of fluoroscopy to cancer care. For decades, interventional radiologists and oncologists have relied on fluoroscopic guidance for:

  • Percutaneous biopsies of suspicious lesions, particularly in the lung, liver, and bone, where real‑time needle tracking reduces complications such as pneumothorax or bleeding.
  • Tumor embolization (e.g., transarterial chemoembolization, TACE) for hepatocellular carcinoma and liver metastases, where fluoroscopy enables catheter navigation and precise delivery of embolic agents.
  • Placement of drainage catheters for symptomatic ascites, pleural effusions, or abscesses, which can be critical in palliative care.
  • Verification of device positioning during port placements, vertebroplasty, or kyphoplasty for metastatic bone lesions.

These applications have proven the value of fluoroscopy’s immediacy and spatial accuracy. However, the field of interventional oncology is now demanding even more: three‑dimensional navigation, fusion with cross‑sectional imaging, and integration with therapeutic modalities. The response has been a wave of innovation that expands fluoroscopy’s utility well beyond its traditional jobs.

Emerging Fluoroscopy‑Guided Ablative Therapies

Radiofrequency and Microwave Ablation

Thermal ablation—using radiofrequency (RFA) or microwave (MWA) energy—has become a standard treatment for small tumors in the liver, kidney, lung, and bone when surgery is not feasible. While these procedures are often performed under CT or ultrasound guidance, fluoroscopy is increasingly employed as a complementary or primary imaging modality, particularly for complex anatomical targets.

Fluoroscopy offers several advantages in ablation. First, it provides real‑time feedback on needle position and trajectory changes during respiratory motion. This is critical for lung nodules that move with each breath. Second, digital subtraction angiography (DSA) can be performed immediately before ablation to outline the tumor’s vascular supply, allowing the operator to adjust the probe path to avoid large vessels. Lastly, cone‑beam CT (CBCT) – a volumetric extension of fluoroscopy – can be obtained at the same table, enabling cross‑sectional confirmation without moving the patient to a separate scanner. This “one‑stop” workflow improves efficiency and reduces anesthesia time.

Emerging applications include combined fluoroscopy and ultrasound guidance, where the two modalities are fused onto a single monitor. The bright, high‑contrast fluoroscopic image helps visualize metallic needles, while ultrasound distinguishes soft‑tissue boundaries. This fusion approach has been shown to reduce the number of needle passes and complication rates in liver and renal ablations.

Cryoablation and Irreversible Electroporation

Beyond thermal methods, non‑thermal ablative techniques such as cryoablation and irreversible electroporation (IRE) are gaining traction. Fluoroscopy is used to monitor ice‑ball formation during cryoablation (ice appears as a radiolucent area on the fluoroscopic image) and to verify probe spacing during IRE, where precise electrode placement is essential for creating a sufficient electric field. The ability to capture real‑time changes in tissue density (as ice forms or as gas bubbles appear during IRE) allows the operator to halt or adjust treatment if the ablation zone encroaches on critical structures like the bowel or ureter.

Fluoroscopy‑Guided Combination Therapies: The Rise of Chemoembolization and Radioembolization

Transarterial Chemoembolization (TACE) with Advanced Imaging

TACE remains a mainstay for intermediate‑stage hepatocellular carcinoma. Traditional TACE relies on fluoroscopic angiography to guide a catheter into the hepatic artery branches feeding the tumor. However, emerging techniques now integrate cone‑beam CT (CBCT) acquired with the same C‑arm system. This allows the operator to obtain a 3D roadmap of the tumor’s vascular supply, identify extrahepatic feeders, and detect incomplete embolization in real time.

Additionally, fluoroscopy with digital subtraction angiography (DSA) at multiple angles (rotational angiography) can generate a 3D vascular reconstruction. When overlaid onto a pre‑procedure CT or MRI, this fused image helps predict which tumor segments will be devascularized. Studies have shown that CBCT‑guided TACE improves complete response rates and reduces the number of treatment sessions compared to conventional TACE.

Y‑90 Radioembolization

Selective internal radiation therapy (SIRT) using Yttrium‑90 microspheres is another evolving application where fluoroscopy is indispensable. After planning angiography, technicians map the hepatic vasculature and often perform a “scout” injection of Technetium‑99m macroaggregated albumin under fluoroscopic observation to simulate microsphere distribution. During the actual Y‑90 infusion, fluoroscopy ensures the microcatheter remains in the desired position and that no reflux occurs. Cone‑beam CT with contrast can further verify that the delivery is confined to the target lobe or segment, minimizing radiation‑induced liver disease.

Integration with Immunotherapy and Targeted Agents

One of the most exciting frontiers is the use of fluoroscopy to guide the local delivery of immunomodulators, oncolytic viruses, and gene therapy vectors. Rather than systemic administration, these agents can be injected directly into the tumor or its draining lymphatics under fluoroscopic guidance. The real‑time capability of fluoroscopy enables the interventionalist to monitor the spread of the injectate (often mixed with a contrast agent) and adjust needle position if the distribution is suboptimal.

For example, in hepatic artery infusion (HAI) pumps, fluoroscopy confirms catheter tip placement in the gastroduodenal artery or proper hepatic artery, and it verifies that the pump chamber is filling correctly. Newer protocols combine HAI with systemic checkpoint inhibitors, and fluoroscopic surveillance of the catheter position at each treatment cycle ensures consistent delivery.

Fluoroscopic Monitoring of Treatment Response

Beyond guiding interventions, fluoroscopy is being harnessed to assess real‑time physiological changes during treatment. For instance, during chemoembolization, contrast‑enhanced fluoroscopy can show the degree of vascular stasis and contrast retention within the tumor, serving as an immediate surrogate for treatment effect. Similarly, during ablation, contrast agents can be injected to evaluate the ablation zone’s border – a technique known as “ablation defect mapping.”

Another emerging use is dynamic cone‑beam CT perfusion, which leverages a series of fluoroscopic acquisitions during contrast injection to calculate blood flow, blood volume, and permeability parameters. This functional imaging can be performed immediately before and after an intervention, giving the operator quantitative feedback on whether the treatment achieved its goal (e.g., reduced tumor perfusion). This is particularly valuable for assessing response in renal and lung tumors, where traditional size‑based criteria may not reflect early changes.

Advanced Navigational Platforms and Robotics

Fluoroscopy is increasingly paired with electromagnetic or optical tracking systems to create augmented reality overlays. For example, a pre‑operative CT or MRI can be segmented to display the tumor, major vessels, and airways, and then registered to the patient’s anatomy using fluoroscopic landmarks. During the procedure, the operator sees a fused image on the monitor, with the real‑time fluoroscopic image superimposed on the 3D model. This greatly enhances spatial orientation for complex targets such as pulmonary nodules located near the mediastinum or for spinal metastases adjacent to the spinal cord.

Robotic assistance is another frontier. Platforms like the Corindus (now Siemens) robotic system enable precise catheter and guidewire manipulation from a control room, reducing radiation exposure to the operator. While primarily used in coronary interventions, its application in oncologic embolization is being investigated. The combination of robotic‑assisted manipulation and fluoroscopic guidance could improve consistency and reduce procedure times for complex tumor arterial supply.

Pediatric and Special Populations

Emerging use cases also expand fluoroscopy’s role in pediatric interventional oncology. Children with liver tumors, Wilms tumor, or bone sarcomas often require precise embolization or ablation with minimal radiation dose. Modern fluoroscopy systems with optimized pulse rates (as low as 3.75 frames per second) and advanced image processing (e.g., iterative reconstruction) allow significantly reduced dose while maintaining image quality. Additionally, the use of low‑contrast iodinated agents and carbon dioxide (CO2) angiography under fluoroscopy helps avoid nephrotoxicity and contrast reactions in this vulnerable population.

Furthermore, for patients with metal implants, orthopedic hardware, or previously placed stents, fluoroscopy remains the most reliable modality for visualizing device interaction with tumor tissue. Unlike CT or MRI, it does not suffer from severe metal artifact, making it indispensable for guiding biopsies or ablations through the “window” of a spinal cage or around a femoral nail.

External Support and Evidence

Several clinical studies underscore these advancements. For example, a 2021 systematic review in CardioVascular and Interventional Radiology found that cone‑beam CT guidance during TACE improved tumor response rates by 12‑15% compared to conventional DSA alone. Another trial published in Radiology (2022) demonstrated that fluoroscopy‑fusion guidance for lung ablation reduced the pneumothorax rate from 38% to 18%. The Society of Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe both endorse the integration of advanced fluoroscopic techniques into oncologic practice.

Future Directions

Looking ahead, research is focusing on several areas:

  • Artificial intelligence (AI) for automated segmentation and motion compensation: AI algorithms can pre‑process fluoroscopic images to subtract bones, enhance contrast, and predict respiratory motion, enabling more accurate targeting.
  • Multimodal fusion with real‑time MRI: Hybrid systems that combine fluoroscopy with an open MRI scanner are in development, allowing instant cross‑tabulation of vascular anatomy (from fluoroscopy) with soft‑tissue detail (from MRI) without moving the patient.
  • Theranostic applications: Using fluoroscopy to guide the delivery of injectables that both treat and image (e.g., radiopaque drug‑eluting beads) could allow real‑time pharmacokinetic monitoring.
  • Remote proctoring and tele‑intervention: With advanced network connectivity, an expert interventionalist could supervise a complex fluoroscopic procedure from a distant site, expanding access to specialized care.

The development of phase‑contrast fluoroscopy – a technique that detects subtle differences in tissue density using X‑ray phase shifts rather than absorption – could dramatically improve contrast for soft‑tissue tumors without increasing radiation dose. While still in early preclinical stages, such advances may eventually make fluoroscopy competitive with ultrasound and MRI for guiding interstitial therapies.

Challenges and Considerations

Despite its promise, expanded use of fluoroscopy in interventional oncology is not without challenges. Radiation exposure to both patient and operator remains a concern, especially when procedures become longer or more complex. Strict adherence to ALARA (As Low As Reasonably Achievable) principles, the use of dose‑reducing technology, and periodic staff training are essential. Additionally, the integration of advanced imaging tools (CBCT, fusion, robotics) requires significant capital investment and operator education. Facilities must balance the benefits against cost and workflow impact.

Another limitation is the two‑dimensional nature of standard fluoroscopy. Even with rotational acquisitions, the operator must mentally reconstruct three‑dimensional anatomy. CBCT addresses this but at the cost of additional radiation and contrast medium. Future systems that provide real‑time stereoscopic or holographic displays may overcome this hurdle.

Conclusion

Fluoroscopy is undergoing a renaissance in interventional oncology. No longer merely a tool for basic guidance, it now enables precise ablation, combination therapies, local drug delivery, and functional monitoring – all within the same procedural suite. The integration of cone‑beam CT, fusion imaging, robotic assistance, and artificial intelligence will continue to push the boundaries of what can be achieved with X‑ray guidance. As clinical evidence accumulates and technology evolves, fluoroscopy will remain an indispensable modality for interventionalists striving to deliver safer, more effective, and more personalized cancer care.

For further reading, consider the comprehensive review by Gaba et al. in Seminars in Interventional Radiology and the ongoing clinical trials listed at ClinicalTrials.gov regarding fluoroscopy‑guided oncologic interventions.